Clear All
11120 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
NDC-11 (Package) NDC-9 (Product) Generic Name Brand Name Strength SEER*Rx Category Major Class Minor Class Administration Route Package Effective Date Package Discontinuation Date Status
71930-0017-52 71930-0017 Ondansetron Ondansetron 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Feb 6, 2020 In Use
68001-0246-04 68001-0246 Ondansetron Ondansetron 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Feb 13, 2018 In Use
21695-0380-30 21695-0380 Ondansetron Ondansetron 8.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Aug 13, 2007 In Use
71930-0017-30 71930-0017 Ondansetron Ondansetron 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Jul 11, 2018 In Use
63126-0331-15 63126-0331 Granisetron Hydrochloride Granisetron Hydrochloride 0.1 mg/mL Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Intravenous Dec 1, 2020 In Use
21695-0835-30 21695-0835 Ondansetron Hydrochloride Ondansetron Hydrochloride 8.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Jun 25, 2007 In Use
89141-0444-30 89141-0444 Ondansetron Zuplenz 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Dec 31, 2016 Feb 23, 2023 No Longer Used
50268-0622-11 50268-0622 Ondansetron Hydrochloride Ondansetron Hydrochloride 8.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Aug 5, 2016 In Use
71930-0018-52 71930-0018 Ondansetron Ondansetron 8.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Feb 6, 2020 In Use
72266-0124-01 72266-0124 Ondansetron Ondansetron 2.0 mg/mL Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Intramuscular, Intravenous Apr 2, 2019 In Use
72266-0123-25 72266-0123 Ondansetron Ondansetron 2.0 mg/mL Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Intramuscular, Intravenous Apr 2, 2019 In Use
21695-0834-04 21695-0834 Ondansetron Hydrochloride Ondansetron Hydrochloride 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Jun 25, 2007 In Use
21695-0834-12 21695-0834 Ondansetron Hydrochloride Ondansetron Hydrochloride 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Jun 25, 2007 In Use
21695-0834-15 21695-0834 Ondansetron Hydrochloride Ondansetron Hydrochloride 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Jun 25, 2007 In Use
00078-1196-20 00078-1196 Asciminib SCEMBLIX 100.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor ABL/BCR-ABL1 Oral Apr 18, 2024 In Use
00078-1098-94 00078-1098 asciminib SCEMBLIX 40.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor ABL/BCR-ABL1 Oral Oct 29, 2021 In Use
00078-1098-30 00078-1098 asciminib SCEMBLIX 40.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor ABL/BCR-ABL1 Oral Oct 29, 2021 In Use
00078-1098-20 00078-1098 asciminib SCEMBLIX 40.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor ABL/BCR-ABL1 Oral Oct 29, 2021 In Use
00078-1091-20 00078-1091 asciminib SCEMBLIX 20.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor ABL/BCR-ABL1 Oral Oct 29, 2021 In Use
00078-1091-94 00078-1091 asciminib SCEMBLIX 20.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor ABL/BCR-ABL1 Oral Oct 29, 2021 In Use
68727-0712-01 68727-0712 Lurbinectedin ZEPZELCA 0.5 mg/mL Chemotherapy Alkylating Agent Adduct Forming Agent Intravenous Jun 15, 2020 In Use
00015-3080-60 00015-3080 Mitotane Lysodren 500.0 mg/1 Chemotherapy Miscellaneous Agent Adrenal Suppressant Oral Jun 1, 2009 Mar 31, 2021 No Longer Used
00310-9501-01 00310-9501 Capivasertib TRUQAP 200.0 mg/1 Chemotherapy AKT Inhibitor AKT1/2/3 Oral Nov 16, 2023 In Use
00310-9500-01 00310-9500 Capivasertib TRUQAP 160.0 mg/1 Chemotherapy AKT Inhibitor AKT1/2/3 Oral Nov 16, 2023 In Use
00310-9501-02 00310-9501 Capivasertib TRUQAP 200.0 mg/1 Chemotherapy AKT Inhibitor AKT1/2/3 Oral Oct 18, 2024 In Use

Found 11120 results — Export these results